Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Files An 8-K Other Events

Item 8.01.

On May 8, 2017, Accelerate Diagnostics, Inc. (the Company) issued
a press release announcing a proposed underwritten public
offering of shares of its common stock (the Offering). A copy of
the Companys press release is attached hereto as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by
reference in its entirety.

On May 9, 2017, the Company issued a press release announcing the
pricing of the Offering. A copy of the Companys press release is
attached hereto as Exhibit 99.2 to this Current Report on Form
8-K and is incorporated herein by reference in its entirety.

About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Recent Trading Information

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) closed its last trading session down -0.73 at 28.12 with 630,986 shares trading hands.